Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18760224 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2CPB2EPHX2HDAC4HDAC1 | |
| SCHEMBL18760223 | 0.94 | SMN1; SMN2 (0.52) | SMN1; SMN2CPB2EPHX2CXCR4 | |
| SCHEMBL23840017 | 0.80 | NMT1 (0.46) | — | |
| SCHEMBL18760192 | 0.80 | NMT1 (0.46) | — | |
| SCHEMBL22054640 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2EPHX2HDAC4HDAC1CXCR4 | |
| SCHEMBL20792784 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2EPHX2HDAC4HDAC1CXCR4 | |
| SCHEMBL20634649 | 0.79 | NMT1 (0.48) | — | |
| SCHEMBL20633846 | 0.79 | NMT1 (0.48) | — | |
| SCHEMBL24220957 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2EPHX2HDAC4HDAC1CXCR4 | |
| SCHEMBL23840151 | 0.77 | NMT1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112941-A1 | VE-CADHERIN BINDING BIOCONJUGATE | SYMIC IP, LLC | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112941-A1 | VE-CADHERIN BINDING BIOCONJUGATE | EPCAM, CDH1, VCAM1 | SMN1; SMN2 4585/4885CPB2 743/4885EPHX2 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.